Search research articles
Contact Us
Filters
Showing results (451-460 of 474) with videos related to
Page
of 48
Sort By:
JAMA Network Open
|
October 9, 2024
Psychological Distress Among Ethnically Diverse Participants From Eastern and Southern Africa
Kester B B Tindi, Allan Kalungi, Eugene Kinyanda, et al.
The Lancet. Oncology
|
April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2021
Reply to E. Hindié
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
The Lancet. Oncology
|
April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
American Journal of Human Genetics
|
March 26, 2021
Low-coverage sequencing cost-effectively detects known and novel variation in underrepresented populations
Alicia R Martin, Elizabeth G Atkinson, Sinéad B Chapman, et al.
Page
of 48
Search research articles
Search
Showing results (451-460 of 474) with videos related to
Sort By:
Page
of 48
JAMA Network Open
|
October 9, 2024
Psychological Distress Among Ethnically Diverse Participants From Eastern and Southern Africa
Kester B B Tindi, Allan Kalungi, Eugene Kinyanda, et al.
The Lancet. Oncology
|
April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2021
Reply to E. Hindié
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassee, Michal Kicinski, et al.
The Lancet. Oncology
|
April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.
American Journal of Human Genetics
|
March 26, 2021
Low-coverage sequencing cost-effectively detects known and novel variation in underrepresented populations
Alicia R Martin, Elizabeth G Atkinson, Sinéad B Chapman, et al.
Page
of 48